Prasinezumab shows signs of slowing motor symptom decline in early stage Parkinson’s

Prasinezumab shows signs of slowing motor symptom decline in early stage Parkinson’s
A protein called alpha-synuclein builds up in the brains of people with Parkinson's. This accumulation is believed to play a role in the progressive nature of Parkinson's. Biotech companies have been developing treatments that can remove excess alpha-synuclein, in the hope of slowing/stopping the progression of Parkinson's. One type of treatment being developed is called immunotherapy. Immunotherapy involves artificially boosting ... read more
Source: The Cure Parkinson’s TrustPublished on 2020-09-22